AU2020388973A1 - Medical uses of 4-1BBL adjuvanted recombinant modified vaccinia virus ankara (MVA) - Google Patents

Medical uses of 4-1BBL adjuvanted recombinant modified vaccinia virus ankara (MVA) Download PDF

Info

Publication number
AU2020388973A1
AU2020388973A1 AU2020388973A AU2020388973A AU2020388973A1 AU 2020388973 A1 AU2020388973 A1 AU 2020388973A1 AU 2020388973 A AU2020388973 A AU 2020388973A AU 2020388973 A AU2020388973 A AU 2020388973A AU 2020388973 A1 AU2020388973 A1 AU 2020388973A1
Authority
AU
Australia
Prior art keywords
tumor
mva
bbl
taa
recombinant mva
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2020388973A
Other languages
English (en)
Inventor
Matthias Habjan
Jürgen HAUSMANN
Maria HINTERBERGER
Markus Kalla
Jose Medina Echeverz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bavarian Nordic AS
Original Assignee
Bavarian Nordic AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bavarian Nordic AS filed Critical Bavarian Nordic AS
Publication of AU2020388973A1 publication Critical patent/AU2020388973A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2020388973A 2019-11-20 2020-11-20 Medical uses of 4-1BBL adjuvanted recombinant modified vaccinia virus ankara (MVA) Pending AU2020388973A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
EP19210369.5 2019-11-20
EP19210369 2019-11-20
EP20191226.8 2020-08-14
EP20191226 2020-08-14
EP20193706.7 2020-08-31
EP20193706 2020-08-31
PCT/EP2020/082888 WO2021099572A1 (en) 2019-11-20 2020-11-20 Medical uses of 4-1bbl adjuvanted recombinant modified vaccinia virus ankara (mva)

Publications (1)

Publication Number Publication Date
AU2020388973A1 true AU2020388973A1 (en) 2022-05-26

Family

ID=73455743

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020388973A Pending AU2020388973A1 (en) 2019-11-20 2020-11-20 Medical uses of 4-1BBL adjuvanted recombinant modified vaccinia virus ankara (MVA)

Country Status (11)

Country Link
US (1) US20230059344A1 (enExample)
EP (1) EP4061404A1 (enExample)
JP (1) JP7670705B2 (enExample)
KR (1) KR20220116191A (enExample)
CN (1) CN114929268A (enExample)
AU (1) AU2020388973A1 (enExample)
BR (1) BR112022009797A2 (enExample)
CA (1) CA3159666A1 (enExample)
IL (1) IL293012A (enExample)
MX (1) MX2022005601A (enExample)
WO (1) WO2021099572A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111050790B (zh) * 2017-08-24 2024-07-12 巴法里安诺迪克有限公司 通过静脉内施用重组mva和抗体治疗癌症的组合疗法
US12194157B2 (en) 2020-04-09 2025-01-14 Finncure Oy Carrier for targeted delivery to a host
FI20215508A1 (en) 2020-04-09 2021-10-10 Niemelae Erik Johan Mimetic nanoparticles to prevent the spread of new coronaviruses and reduce the rate of infection
CN117004579B (zh) * 2023-06-29 2024-11-15 苏州恩立维生物科技有限公司 重组溶瘤牛痘病毒及其应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6969609B1 (en) * 1998-12-09 2005-11-29 The United States Of America As Represented By The Department Of Health And Human Serivces Recombinant vector expressing multiple costimulatory molecules and uses thereof
UA76731C2 (uk) 2000-11-23 2006-09-15 Баваріан Нордік А/С Штам mva-bn модифікованого вірусу коров'ячої віспи ankara, фармацевтична композиція, вакцина, застосування mva-bn для приготування лікарського препарату та для приготування вакцини, спосіб введення гомологічної і/або гетерологічної послідовності нуклеїнової кислоти в клітини-мішені in vitro, спосіб одержання пептиду або білка, спосіб одержання mva-bn, клітина, набір для основної/бустерної імунізації
EP2345665A3 (en) 2001-12-04 2012-02-15 Bavarian Nordic A/S Flavivirus NS1 subunit vaccine
US8691502B2 (en) * 2008-10-31 2014-04-08 Tremrx, Inc. T-cell vaccination with viral vectors via mechanical epidermal disruption
MX367100B (es) * 2012-02-17 2019-08-05 The Children´S Hospital Of Philadelphia Composiciones del vector aav y metodos para su transferencia genetica a celulas, organos y tejidos.
WO2014037124A1 (en) * 2012-09-04 2014-03-13 Bavarian Nordic A/S Methods and compositions for enhancing vaccine immune responses
CA2942501A1 (en) * 2014-03-17 2015-09-24 Tapimmune Inc. Nucleic acid molecule vaccine compositions and uses thereof
KR102499737B1 (ko) * 2014-05-13 2023-02-13 버베리안 노딕 에이/에스 종양 항원을 발현하는 재조합 폭스바이러스 및 면역 체크포인트 분자 길항제 또는 효현제로 암을 치료하기 위한 복합 요법
WO2017120577A1 (en) 2016-01-08 2017-07-13 Geovax Inc. Compositions and methods for generating an immune response to a tumor associated antigen
IL261321B2 (en) * 2016-02-25 2023-12-01 Memorial Sloan Kettering Cancer Center Recombinant mva or mvadele3l expressing human flt3l and use thereof as immuno-therapeutic agents against solid tumors
WO2017152042A2 (en) * 2016-03-04 2017-09-08 New York University Virus vectors expressing multiple epitopes of tumor associated antigens for inducing antitumor immunity
CN111050790B (zh) 2017-08-24 2024-07-12 巴法里安诺迪克有限公司 通过静脉内施用重组mva和抗体治疗癌症的组合疗法
US20190345516A1 (en) * 2018-03-12 2019-11-14 Musc Foundation For Research Development Methods for treating eye disease
CA3119503A1 (en) 2018-11-20 2020-05-28 Bavarian Nordic A/S Therapy for treating cancer with an intratumoral and/or intravenous administration of a recombinant mva encoding 4-1bbl (cd137l) and/or cd40l

Also Published As

Publication number Publication date
MX2022005601A (es) 2022-08-15
JP2023503858A (ja) 2023-02-01
EP4061404A1 (en) 2022-09-28
CA3159666A1 (en) 2021-05-27
KR20220116191A (ko) 2022-08-22
WO2021099572A1 (en) 2021-05-27
IL293012A (en) 2022-07-01
BR112022009797A2 (pt) 2022-08-16
CN114929268A (zh) 2022-08-19
JP7670705B2 (ja) 2025-04-30
US20230059344A1 (en) 2023-02-23

Similar Documents

Publication Publication Date Title
US9744224B2 (en) Methods for treating cancer by administration of nucleic acids encoding FAP and cancer antigens
ES2715890T3 (es) Vectores de expresión de antígenos asociados a la próstata
KR102684237B1 (ko) 개인 맞춤형 백신
EP2958994B1 (en) Vaccine composition
JP7670705B2 (ja) ４－１ｂｂｌアジュバント添加した組み換え改変ワクシニアウイルスアンカラ（ｍｖａ）の医学的使用
Mastrangelo et al. Poxvirus vectors: orphaned and underappreciated
US20170016026A1 (en) Chimeric nucleic acid molecules with non-aug translation initiation sequences and uses thereof
KR20180119659A (ko) 항종양 면역을 유도하기 위한 종양 관련 항원의 다중 에피토프를 발현하는 바이러스 벡터
CN106061509B (zh) 编码端粒酶的dna疫苗
EP3077408A1 (en) Molecular adjuvant
US12180501B2 (en) Viral vectors encoding cancer/testis antigens for use in a method of prevention or treatment of cancer
RU2380375C2 (ru) Слитые белки карциноэмбрионального антигена
Aurisicchio et al. Immunogenicity and safety of a DNA prime/adenovirus boost vaccine against rhesus CEA in nonhuman primates
JP5285855B2 (ja) 膵癌を処置および予防するためのカスタムベクター
Odin et al. Canarypox virus expressing wild type p53 for gene therapy in murine tumors mutated in p53
Komant et al. Oncolytic vaccinia virus as a precision cancer vaccine platform
US20240009257A1 (en) Methods and materials for treating cancer
Bella-Carreño et al. Synergistic antitumor response with recombinant modified virus Ankara armed with CD40L and CD137L against peritoneal carcinomatosis
Hartman et al. Utility of Adenovirus-Based Vectors for Multiple Cancer Vaccine Approaches
HK1182137A (en) Methods and compositions using listeria for adjuvant treatment of cancer